InvestorsHub Logo
Followers 8
Posts 795
Boards Moderated 0
Alias Born 01/18/2010

Re: None

Tuesday, 05/03/2011 8:55:30 AM

Tuesday, May 03, 2011 8:55:30 AM

Post# of 3195
Alexza Prices $16.1 Million Registered Direct Offering
Date : 05/03/2011 @ 8:30AM
Source : PR Newswire
Stock : Alexza (ALXA)
Quote : 1.63 0.0 (0.00%) @ 7:22AM


Alexza Prices $16.1 Million Registered Direct Offering

Alexza (NASDAQ:ALXA)
Intraday Stock Chart
Today : Tuesday 3 May 2011
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), or the Company, today announced that it has entered into a definitive agreement with three institutional investors, including RA Capital Management and Tavistock Life Sciences, to raise approximately $16.1 million in gross proceeds in a registered direct offering through the sale of common stock and warrants. The Company agreed to sell a total of 11,927,034 units, each unit consisting of (i) one share of common stock and (ii) one warrant to purchase 0.35 of a share of common stock, at a purchase price of $1.35 per unit. The warrants will be exercisable six months after issuance at $1.755 per share and will expire five years from the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.

Alexza estimates that net proceeds from the offering will be approximately $15.8 million, after deducting estimated offering expenses. The Company intends to use the net proceeds from the sale of the securities primarily for general corporate purposes, including regulatory activity, clinical trial, research and development, general and administrative and manufacturing expenses.

The securities described above are being offered pursuant to a registration statement on Form S3 previously declared effective by the Securities and Exchange Commission on May 20, 2010. The transaction is expected to close on or about May 6, 2011, subject to customary closing conditions.

A copy of the prospectus supplement relating to the offering and the accompanying base prospectus may be obtained by contacting Alexza Pharmaceuticals, Inc., Attention: Corporate Secretary, 2091 Stierlin Court, Mountain View, California 94043, or by calling (650) 944-7000. A copy of the prospectus supplement relating to the offering and the accompanying base prospectus may also be accessed on the SEC website, http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Alexza nor shall there be any sale of such securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.


Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.